[Federal Register Volume 69, Number 219 (Monday, November 15, 2004)]
[Notices]
[Pages 65609-65610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-25278]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Metal Chelators and Target-Moiety Complexes for Imaging

Martin W. Brechbiel and Thomas Clifford (NCI).
U.S. Provisional Application filed 23 Aug 2004 (DHHS Reference No. E-
317-2004).
Licensing Contact: Michael Shmilovich; 301/435-5019; 
<a href="/cdn-cgi/l/email-protection#bfccd7d2d6d3d0c9d2ffd2ded6d391d1d6d791d8d0c9"><span class="__cf_email__" data-cfemail="aeddc6c3c7c2c1d8c3eec3cfc7c280c0c7c680c9c1d8">[email protected]</span></a>.

    Available for licensing and commercial development are bifunctional 
metal chelators, metal chelator-targeting moiety complexes, metal 
chelator-targeting moiety-metal conjugates, kits, and methods of 
preparing them. These chelators are useful in diagnosing and/or 
treatment of cancer and thrombosis. The metal chelators may be used in 
conventional and solid-phase synthetic methods to form targeting 
moieties (e.g., peptides, and Starburst polyamidoamine dendrimers 
(PAMAM), capable of conjugating diagnostic and/or therapeutic metals. 
The formulae for two such chelators is shown below:
[GRAPHIC] [TIFF OMITTED] TN15NO04A.054

Anti-HIV Peptide Secreting Bacteria: Therapeutics and Methods of Use

Dean Hamer (NCI).
U.S. Provisional Application No. 60/604,051 filed 25 Aug 2004 (DHHS 
Reference No. E-233-2004/0-US-01).
Licensing Contact: Michael Shmilovich; 301/435-5019; 
<a href="/cdn-cgi/l/email-protection#9ae9f2f7f3f6f5ecf7daf7fbf3f6b4f4f3f2b4fdf5ec"><span class="__cf_email__" data-cfemail="83f0ebeeeaefecf5eec3eee2eaefadedeaebade4ecf5">[email protected]</span></a>.

    Available for licensing and commercial development are genetically

[[Page 65610]]

engineered commensal bacteria compositions that secrete HIV infectivity 
interfering peptides with the aid of co-expressed translocation 
mediators such as HylB, HylD or tolC gene products. The bacteria can 
be, for example, Escherichia coli and are preferably those that 
colonize the gastrointestinal or genitourinary tracts. The secreted 
anti-HIV peptide can be a functional inhibitory fragment from the C-
terminus of HIV, SHIV or SIV, or an inhibitory peptide derived from the 
N-terminus receptor-binding domain of SIV gp41, HIV-1 gp41, or HIV-2 
gp41. The secreted anti-HIV peptide can also be a peptide from the 
allosteric domain of gp120, an extracellular loop of CCR5, an anti-CD4 
immunoglobulin, a mimetic of CD4, an alpha-defensin or theta-defensin, 
a CD38 fragment homologous to the V3 loop of gp120, polphemusin II (a 
CXCR4 antagonist), a RANTES peptide that binds to CCR5 or an HIV 
surface binding peptide such as cyanovirin.

Method of Assessing Ischemia in a Patient

Steven Warach, Lawrence Latour (NINDS).
U.S. Provisional Application No. 60/381,611 filed 17 Mar 2002 (DHHS 
Reference No. E-082-2002/0-US-01); PCT Application No. PCT/US03/15368 
filed 16 May 2003 (DHHS Reference No. E-082-2002/0-PCT-02).
Licensing Contact: Michael Shmilovich; 301/435-5019; 
<a href="/cdn-cgi/l/email-protection#cbb8a3a6a2a7a4bda68ba6aaa2a7e5a5a2a3e5aca4bd"><span class="__cf_email__" data-cfemail="b8cbd0d5d1d4d7ced5f8d5d9d1d496d6d1d096dfd7ce">[email protected]</span></a>.

    Hyperintense acute reperfusion marker (HARM) is well correlated 
with reperfusion and is a precursor to or concomitant with reperfusion 
injury. The inventors have developed a novel technique of assessing 
injuries associated with ischemia, stroke, or reperfusion injury in a 
patient by administering a contract agent to the patient, acquiring a 
fluid-attenuated inversion-recovery (FLAIR) image, and observing the 
presence or absence of HARM on the acquired image. The technique can 
also be used to determine the effectiveness of a therapeutic protocol 
for the treatment or prevention of reperfusion injury in a patient that 
has previously suffered an ischemic event.
    This research has been described, in part, in Latour et al., 
``Early Blood-Brain Barrier Disruption in Human Focal Brain Ischemia,'' 
Ann. Neurol. 2004 56:568-477.

    Dated: November 4, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-25278 Filed 11-12-04; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>